Akari Therapeutics (AKTX) Accumulated Depreciation (2018 - 2020)

Akari Therapeutics (AKTX) has reported Accumulated Depreciation for 3 consecutive years, with $164938.0 the latest figure, recorded in Q4 2020.

• Quarterly Accumulated Depreciation rose 3.13% year-over-year to $164938.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $164938.0 (up 3.13% YoY) and the FY2020 annual result came in at $164938.0, up 3.13% from the prior year.
• Accumulated Depreciation was little changed at $164938.0 in Q4 2020 per AKTX's latest filing, from $164938.0 in the prior quarter.
• Over the last five years, Accumulated Depreciation for AKTX reached as high as $164938.0 in Q2 2020 and fell as low as $144513.0 in Q4 2018.
• A 3-year average of $158578.5 and a median of $162431.5 in 2019 frame the typical range for Accumulated Depreciation.
• Annual changes were most pronounced in 2019 — Accumulated Depreciation rose 10.66% — and 2020, when it increased 3.13%.
• Year by year, Accumulated Depreciation stood at $144513.0 in 2018, then rose by 10.66% to $159925.0 in 2019, then rose by 3.13% to $164938.0 in 2020.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $164938.0, $164938.0, and $159925.0 for Q4 2020, Q2 2020, and Q4 2019 respectively.